Physician profile
David O Johnson
NPI 1740204692
$629.66
in general payments reported to CMS, 2019-2025
16 companies · $17.86 in 2025
The $17.86 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $64.90 · 2021: $167 · 2022: $141 · 2023: $87.85 · 2025: $17.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $105.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $233.05 | 2019-2023 | Shingrix, Bexsero, Pediarix |
| Genentech USA, INC. | $72.36 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $56.99 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $45.64 | 2021 | |
| Cranial Technologies, INC | $42.15 | 2019-2023 | Doc Band |
| Sanofi Pasteur INC. | $26.26 | 2019-2022 | |
| Pfizer INC. | $17.86 | 2025 | |
| Esperion Therapeutics, INC. | $17.84 | 2021 | |
| Antares Pharma, INC. | $17.39 | 2021 | |
| Ironshore Pharmaceuticals INC. | $16.66 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.13 | 2021 | |
| Dexcom, INC. | $15.48 | 2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $13.57 | 2023 | |
| Idorsia Pharmaceuticals US INC | $13.56 | 2022 | |
| Novo Nordisk INC | $12.60 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.